CD8A and renal cell carcinoma: These findings suggest ICB therapy reshapes CD8 + T cells in advanced RCC, with the 4-1BB-Lo subset showing significant activation and differentiation towards terminal exhaustion in responders, providing insights into ICB resistance mechanisms in advanced RCC [226].